Metastatic Castration-resistant Prostate Cancer
Conditions
Brief summary
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
Detailed description
This First in Human dose escalation and expansion study of HP518 in patients with progressive mCRPC after NHA and chemotherapy is being conducted not only to evaluate the safety and tolerability of orally administered HP518, but also to provide preliminary efficacy for the reference of future studies.
Interventions
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
DRUGHP518 -Dose Expansion
Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Sponsors
Hinova Pharmaceuticals Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male, age ≥18 2. Patients with androgen receptor (AR) ligand binding domain (LBD) activation mutations (the dose expansion part of stage II) 3. Has histologically confirmed adenocarcinoma of the prostate, but there are no known significant neuroendocrine differentiation or small cell characteristics. 4. Has metastatic disease documented by 2 or more bone lesions by bone scan or soft tissue disease progression observed by CT/MRI at the beginning of study. 5. the progression of the disease after receiving at least one new endocrine therapy and progressing with at least first-line chemotherapy. 6. Must have recovered from toxicities related to any prior treatments 7. Ongoing ADT with LHRH agonist/antagonist therapy or history of bilateral orchiectomy. 8. ECOG performance status score of 0 to 1.
Exclusion criteria
1. Combination of research or commercially available drugs targeting AR 2. Has had any other anticancer treatments, including immunotherapy, chemotherapy, or radiotherapy (eg, 177LuPSMA-617, radium 223, PARP inhibitor) within 4 weeks prior to the first dose of HP518. 3. Has gastrointestinal disorder affecting absorption (e.g., gastrectomy). 4. Has significant cardiovascular disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1) | 28 DAYS | To evaluate the safety and tolerability and determine the MTD and the RP2D of orally administered HP518 (Part 1) |
| Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness | Through study completion, an average of 1 year | To evaluate the safety of orally administered HP518 (Part 1) |
| Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing | Through study completion, an average of 1 year | To evaluate the safety of orally administered HP518 (Part 1) |
| Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing | Through study completion, an average of 1 year | To evaluate the safety of orally administered HP518 (Part 1) |
| Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing | Through study completion, an average of 1 year | To evaluate the safety of orally administered HP518 (Part 1) |
| PSA50 response rate | 12 weeks | Proportion of patients showing a PSA decline by ≥50% between baseline and Week 12 of dosing with HP518. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| According to PCWG3 | 8 weeks | evaluate PSA50 response rate: PSA decline by≥50% between baseline and 4 weeks/8 weeks/12 weeks( only Part 1) of dosing with HP518 |
| According to PCWG3, evaluate time to PSA progression | Through study completion, an average of 1 year | PCWG3 definition: PSA increase \>25% and \>2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart) nadir, confirmed by progression at 2 time points at least 3 weeks apart) |
| area under the concentration-time curve (AUC) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
| Evaluate the modified best overall response mBOR by investigator | Through study completion, an average of 1 year | According to RECIST (version 1.1) and PCWG3 |
| analyze the efficacy of patients with different AR phenotypes(Part 2) | Through study completion, an average of 1 year | According to genetic testing results |
| Time to radiographic progression by investigator PCWG3 definition | Through study completion, an average of 1 year | using the RECIST v1.1 and PCWG3 definition |
| Maximum concentration (Cmax) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
| Time to maximum concentration (Tmax) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
| Apparent terminal elimination half-life (T1/2) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
| apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
| oral clearance (CL/F) | 12 weeks | Assessment of pharmacokinetic parameters of HP518 |
Countries
China
Contacts
Primary ContactQianrong Xiang
Outcome results
None listed